AstraZeneca Investor Day Presentation Deck

33 Imfinzi: Propensity score matching of COAST (durvalumab arm) with PACIFIC (durvalumab arm) ● Matching variables: Age (<75, ≥75), Race (Asian, Other), Prior therapy (Carboplatin, Cisplatin), Time from last radiation to randomisation (<14 days, >14 days), Best response to prior therapies (PR, SD) and Disease stage at entry (IIIA, IIIB, IIIC) PFS probability 1.0 0.8 0.6 0.4 0.2 0.0 COAST PACIFIC 0 61 61 COAST (durva) 6 Ni m 25 31 PACIFIC (durva) 12 18 +++# +++H 12 18 24 Time from randomisation (months) NW 0 7 H 30 1 Events/patients, n PFS-10 months (95% CI) ORR (conf + unconf), % (n) 36 0 COAST (D) 32/61 38.0% (24.5-51.3%) 24.6% (15) PACIFIC (D) 31/60 44.6% (31.3-57.1%) 24.6% (15) B

View entire presentation